“NFLC is specific to neurons and usually isn’t found in circulation,” says Alicia Algeciras-Schimnich, Ph.D. “But following neuronal injury, NFLC is released into cerebral spinal fluid and then into blood, where it can be detected.”

Closing the gap on accessible, inhibition-resistant CAR-T cell therapy.

Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.

T-cell lymphoma is a group of cancers derived from T-cells, which are cells of the immune system that are critical to immune function. Because there are more than 30 identified subtypes of T-cell lymphoma, it can be difficult to make a definitive diagnosis.

Mayo Clinic Laboratories offers a comprehensive genomic profiling panel for solid tumors called the MayoComplete Solid Tumor Panel. This next-generation sequencing assay — Mayo Clinic Laboratories’ most comprehensive genetic profiling assay to date — assesses for mutations in 514 cancer-related genes that have been shown to have clinical importance.

Mayo Clinic BioPharma Diagnostics executives will attend the upcoming AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago July 24-28 to share with attendees the clinical and research capabilities of Mayo Clinic BioPharma Diagnostics.

New research from Mayo Clinic's Center for Individualized Medicine shows patients with ASXL1-mutant chronic myelomonocytic leukemia possess epigenetic alterations that can trigger harmful genes and accelerate the cancer’s growth.

An alternative, innovative approach to multiple sclerosis testing is now available at Mayo Clinic Laboratories. The immunoglobulin kappa free light chain testing was recently validated by Mayo Clinic researchers and will help physicians diagnose multiple sclerosis, especially in patients with equivocal clinical or radiologic findings.

Mayo Clinic BioPharma Diagnostics will highlight its clinical and research testing capabilities this June at the Drug Information Association’s annual meeting. Actively involved in over 600 clinical trial engagements, Mayo Clinic BioPharma Diagnostics team members will share how collaborations can increase award rates and add value to research initiatives.

Receiving upwards of 40,000 specimens daily, Mayo Clinic Laboratories is a bustling hive of activity with a singular focus: accurately processing every test as efficiently as possible. From areas such as Transportation and Global Logistics to Specimen Distribution, each highly trained staff member involved knows the important role they play in delivering samples where they need to go.

A new Mayo Clinic study demonstrates how targeted genomic testing can play an important role in drug prescribing practices.

A new Mayo Clinic study identifies molecular markers in plasma that can potentially improve the diagnosis of Alzheimer's disease in African Americans.